Search results
Results from the WOW.Com Content Network
Amgen has agreed to snap up clinical-stage biotech Five Prime Therapeutics for an equity value of $1.9 billion, to strengthen the company’s oncology candidates. Five Prime shares surged 78.7% to ...
2021: In March, the company announced it would acquire Five Prime Therapeutics and its lead candidate, bemarituzumab, for $1.9 billion. [93] [94] [95] In the same month, Amgen acquired Rodeo Therapeutics for $720 million. [96] [97] The FDA approved Amgen's Lumakras in May for treatment of patients with KRAS-G12C-mutated non-small cell lung ...
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -21.31% and -41.49%, respectively, for the quarter ended September 2020. ... Do the numbers hold clues to what lies ahead ...
For premium support please call: 800-290-4726 more ways to reach us
This file contains additional information, probably added from the digital camera or scanner used to create or digitize it. If the file has been modified from its original state, some details may not fully reflect the modified file.
Robert W. Duggan (born 1944) is an American billionaire, entrepreneur, philanthropist, biotech executive and health care executive.He is the former CEO of biopharmaceutical company Pharmacyclics [2] and was previously CEO of surgical systems maker Computer Motion from 1997 to 2003. [3]
For premium support please call: 800-290-4726 more ways to reach us
Historical WSJ Prime Rate 1947 to June 2022. Items portrayed in this file depicts. Wall Street Journal prime rate. U.S. prime rate. creator. some value. author name ...